-
Posted by
Two Blokes May 7 -
Filed in
Stock
-
3 views
Sarepta Therapeutics, Inc.'s stock is downgraded to Hold due to underperformance, safety concerns with ELEVIDYS, and increased expenses, despite strong long-term fundamentals. Q1 2025 results show mixed SRPT performance: revenue beat expectations, but EPS missed, and cash reserves dropped significantly. ELEVIDYS uptake slowed by safety concerns and a temporary clinical trial hold, causing reduced revenue guidance and cautious market adoption.
